story of the week
Outcomes of Fulvestrant, Palbociclib, and Avelumab Treatment After Progression on CDK4/6i and Aromatase Inhibitor Therapy for HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
J. Clin. Oncol 2024 Mar 21;[EPub Ahead of Print], EL Mayer, Y Ren, N Wagle, R Mahtani, C Ma, A DeMichele, M Cristofanilli, J Meisel, KD Miller, Y Abdou, EC Riley, R Qamar, P Sharma, S Reid, N Sinclair, M Faggen, CC Block, N Ko, AH Partridge, WY Chen, M DeMeo, V Attaya, A Okpoebo, J Alberti, Y Liu, E Gauthier, HJ Burstein, MM Regan, SM TolaneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.